160 related articles for article (PubMed ID: 4369487)
1. [Antibody response in subjects vaccinated with a recall dose of the Sabin or Salk type vaccine].
Squeri L; Calisto ML; Sindoni L; Mattace-Raso G
Ann Sclavo; 1973; 15(6):569-80. PubMed ID: 4369487
[No Abstract] [Full Text] [Related]
2. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
3. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus.
Ogra PL
N Engl J Med; 1971 Jan; 284(2):59-64. PubMed ID: 4321186
[No Abstract] [Full Text] [Related]
4. [Neutralizing antibodies in the sera of persons vaccinated with intradermal poliovirus vaccine].
Jarzabek Z; Kańtoch M
Przegl Epidemiol; 1984; 38(3):323-6. PubMed ID: 6098935
[No Abstract] [Full Text] [Related]
5. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of poliovirus neutralizing antibodies. A seroepidemiologic survey of vaccinated and unvaccinated women of fertile age.
Moschen ME; Farisano G; Bonello C; Benussi G; Barbone F; Gasparini V; Trivello R
Boll Ist Sieroter Milan; 1987; 66(2):97-100. PubMed ID: 2822063
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
Böttiger M
Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939
[No Abstract] [Full Text] [Related]
8. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
9. Poliomyelitis vaccination in Thailand. I. A pilot study of the administration of live poliomyelitis vaccine.
Sangkawibha N; Tuchinda P; Sakuntanaga P; Sunthornsaratul A; Kunasol P; Bukkavesa S; Ochasanonda P
Southeast Asian J Trop Med Public Health; 1974 Jun; 5(2):171-8. PubMed ID: 4370270
[No Abstract] [Full Text] [Related]
10. [Prospects in the field of the antipolio vaccination (author's transl)].
Focà A
Ann Sclavo; 1980; 22(1):22-6. PubMed ID: 7018412
[TBL] [Abstract][Full Text] [Related]
11. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1987 Dec; 36(48):795-8. PubMed ID: 3119980
[No Abstract] [Full Text] [Related]
12. A note on single- and two-dose immunogenicity tests of inactive virus vaccine in chicks.
Slonim D; Drevo M
J Hyg Epidemiol Microbiol Immunol; 1976; 21(3):368-70. PubMed ID: 1033226
[TBL] [Abstract][Full Text] [Related]
13. Medicine and the media: polio still paralyses (Albert Sabin, Jonas Salk).
Dixon B
Br J Hosp Med; 1977 Dec; 18(6):595. PubMed ID: 342023
[No Abstract] [Full Text] [Related]
14. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
Stenvik M; Hovi L; Siimes MA; Roivainen M; Hovi T
Pediatr Infect Dis J; 1987 Dec; 6(12):1106-10. PubMed ID: 2829105
[TBL] [Abstract][Full Text] [Related]
15. Local antibody response to experimental poliovirus infection in the central nervous system of rhesus monkeys.
Ogra PL; Ogra SS; al-Nakeeb S; Coppola PR
Infect Immun; 1973 Dec; 8(6):931-7. PubMed ID: 4361727
[TBL] [Abstract][Full Text] [Related]
16. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
17. Correlation between vaccine coverage against polio and circulation and genetic evolution of the poliovirus strains isolated in Romania in the framework of the global polio eradication strategy.
Băicuş A; Persu A; Popescu M; Penciu A; Stavri S; Soare A; Grecu N; Szmal C; Oprişan G
Roum Arch Microbiol Immunol; 2009; 68(3):145-50. PubMed ID: 20361534
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
Verdijk P; Rots NY; Bakker WA
Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
[TBL] [Abstract][Full Text] [Related]
19. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
20. Reassessment of the place of inactivated poliomyelitis vaccine in national immunization programmes.
Assaad F
Dev Biol Stand; 1981; 47():275-82. PubMed ID: 6262152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
